Mineralys Therapeutics In... (MLYS)
Mineralys Therapeutics Statistics
Share Statistics
Mineralys Therapeutics has 62.78M shares outstanding. The number of shares has increased by 26.46% in one year.
Shares Outstanding | 62.78M |
Shares Change (YoY) | 26.46% |
Shares Change (QoQ) | 26.15% |
Owned by Institutions (%) | 93.04% |
Shares Floating | 36.97M |
Failed to Deliver (FTD) Shares | 58.95K |
FTD / Avg. Volume | 6.18% |
Short Selling Information
The latest short interest is 1.87M, so 3.76% of the outstanding shares have been sold short.
Short Interest | 1.87M |
Short % of Shares Out | 3.76% |
Short % of Float | 7.94% |
Short Ratio (days to cover) | 7.47 |
Valuation Ratios
The PE ratio is -3.36 and the forward PE ratio is -2.56. Mineralys Therapeutics's PEG ratio is -0.04.
PE Ratio | -3.36 |
Forward PE | -2.56 |
PS Ratio | 0 |
Forward PS | 1.4 |
PB Ratio | 3.12 |
P/FCF Ratio | -3.59 |
PEG Ratio | -0.04 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Mineralys Therapeutics.
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 14.02, with a Debt / Equity ratio of 0.
Current Ratio | 14.02 |
Quick Ratio | 14.02 |
Debt / Equity | 0 |
Debt / EBITDA | 0 |
Debt / FCF | 0 |
Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity | n/a |
Return on Assets | n/a |
Return on Invested Capital | n/a |
Revenue Per Employee | $0 |
Profits Per Employee | $-3.49M |
Employee Count | 51 |
Asset Turnover | 0 |
Inventory Turnover | n/a |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by 8.14% in the last 52 weeks. The beta is 1.51, so Mineralys Therapeutics's price volatility has been higher than the market average.
Beta | 1.51 |
52-Week Price Change | 8.14% |
50-Day Moving Average | 11.78 |
200-Day Moving Average | 12.24 |
Relative Strength Index (RSI) | 50.95 |
Average Volume (20 Days) | 954K |
Income Statement
Revenue | n/a |
Gross Profit | 0 |
Operating Income | -192.4M |
Net Income | -177.81M |
EBITDA | -192.4M |
EBIT | n/a |
Earnings Per Share (EPS) | -3.66 |
Balance Sheet
The company has 114.09M in cash and 0 in debt, giving a net cash position of 114.09M.
Cash & Cash Equivalents | 114.09M |
Total Debt | 0 |
Net Cash | 114.09M |
Retained Earnings | -302.52M |
Total Assets | 205.9M |
Working Capital | 190.71M |
Cash Flow
In the last 12 months, operating cash flow was -166.31M and capital expenditures -96K, giving a free cash flow of -166.41M.
Operating Cash Flow | -166.31M |
Capital Expenditures | -96K |
Free Cash Flow | -166.41M |
FCF Per Share | -3.43 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
MLYS does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | n/a |
FCF Yield | n/a |
Analyst Forecast
The average price target for MLYS is $33, which is 136.6% higher than the current price. The consensus rating is "Buy".
Price Target | $33 |
Price Target Difference | 136.6% |
Analyst Consensus | Buy |
Analyst Count | 3 |
Scores
Altman Z-Score | 31.57 |
Piotroski F-Score | 1 |